Boston Scientific has agreed to buy privately held medical- technology company Cortex from medical-device investor Ajax Health in a deal that bolsters its electrophysiology portfolio.
Boston Scientific on Monday said it will pay an undisclosed amount for Cortex, which is developing a diagnostic mapping solution that may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation, a heart rhythm disorder that affects nearly 38 million people around the world.
The Marlborough, Mass., medical-technology company said Cortex received Food and Drug Administration approval for its OptiMap System, which uses a basket catheter and proprietary algorithm to identify potential active atrial fibrillation sources, in 2023.
Boston Scientific said it expects to complete the acquisition in the first half of 2025, adding that it expects the deal to be immaterial impact to adjusted per-share earnings next year.
Ajax Health, which operates as a platform for investing in and operating medical-device companies, established Cortex last year with a $90 million funding led by KKR and Hellman & Friedman.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.